IGF2 and colorectal carcinoma: For instance, patients with esophageal adenocarcinoma (EAC) <65 years old with IGF2 LOI were found to have longer 5-year disease-free survival (DFS) (24), whereas in patients with CRC, the LOI was associated with higher overall mortality (4).